"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

The VGChartz sales comparison series of articles are updated monthly and each one focuses on a different sales comparison using our estimated video game hardware figures. The charts include ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

There are multiple options across multiple issuers, and their rewards and benefits tend to increase in step with the annual fee you pay. Many or all of the products on this page are from partners ...

At close: May 1 at 3:31:23 PM EDT ...

CNET staff -- not advertisers, partners or business interests -- determine how we review products and services. If you buy through our links, we may earn a commission.

David Coghill; Tobias Banaschewski; Alessandro Zuddas; Antonio Pelaz; Antonella Gagliano; Manfred Doepfner ...